Diabetes­hjälpmedel för en enklare vardag.

Tandem t:slim X2™ och Dexcom CGM ger dig med typ 1-diabetes mer tid till annat i livet. Insulinpumpsystemet kan mäta och förutse din glukosnivå, för att automatiskt kunna anpassa insulindoseringen.

Tandem t:slim X2 integreras med Dexcom G7

Tryggt och enkelt att använda

Med Control-IQ™-teknologin får du ett avancerat, kalibreringsfritt insulinpumpsystem som är enkelt att använda. Tandem t:slim X2 insulinpump samarbetar med både Dexcom G7 och Dexcom G6 CGM.

Referenser

• Beck RW, Kanapka LG, Breton MD, Brown SA, Wadwa RP, Buckingham BA, et al. A meta-analysis of randomized trial outcomes for the t:slim X2 insulin pump with Control-IQ technology in youth and adults from age 2 to 72. Diabetes Technol Ther. 2023;25(5). doi:10.1089/dia.2022.0558.
• Bismuth E, Tubiana-Rufi N, Rynders CA, Dalla-Vale F, Bonnemaison E, Coutant R, et al. Sustained 3-year improvement of glucose control with hybrid closed loop in children with type 1 diabetes while going through puberty. Diabetes Care. 2024. doi:10.2337/dc24-0916.
• Breton MD, Kanapka LG, Beck RW, et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med. 2020;383(9):836-845. doi:10.1056/NEJMoa2004736.
• Breton MD, Kovatchev BP. One year real-world use of the Control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021;23(9). doi:10.1089/dia.2021.0097.
• Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019 Oct 16;381(18):1707-1717. doi:10.1056/NEJMoa1907863.
• De Meulemeester J, Keymeulen B, De Block C, et al. One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study. Diabetologia. 2025.
• Kanapka LG, Wadwa RP, Breton MD, et al. Extended use of the Control-IQ closed-loop control system in children with type 1 diabetes. Diabetes Care. 2021;44(2):473–478. doi:10.2337/dc20-1729.
• Renard E, Joubert M, Villard O, et al. Safety and efficacy of sustained automated insulin delivery compared with sensor and pump therapy in adults with type 1 diabetes at high risk for hypoglycemia: A randomized controlled trial. Diabetes Care. 2023;46(12):2180-2187. doi:10.2337/dc23-0685